Recently, the Trump Administration announced plans to initiate a new Section 301 investigation into foreign drug pricing policies, which it argues force Americans to bear an outsized share of the global cost of pharmaceutical innovation. The proposed probe would examine whether U.S. trading partners are paying less than their fair share for prescription drugs. Learn more about the USTR Section 301 investigation. To learn more about the USTR’s role in prescription drug affordability read Aimed Alliance’s the The Art of the Trade: Understanding the USTR.
Last Updated on April 4, 2026 by Aimed Alliance
